Skip to main content
OTCMKTS:MLLCF

Molecular Partners Competitors

$22.48
+0.09 (+0.38 %)
(As of 05/14/2021 03:05 PM ET)
Add
Compare
Today's Range
$22.28
$23.00
50-Day Range
$22.40
$26.25
52-Week Range
$16.00
$33.00
Volume1,451 shs
Average Volume4,923 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Molecular Partners (OTCMKTS:MLLCF) Vs. DDXS, TNGN, ATTBF, ADTX, AGNPF, and LBTSF

Should you be buying MLLCF stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Molecular Partners, including (DDXS) (DDXS), (TNGN) (TNGN), Abattis Bioceuticals (ATTBF), ADiTx Therapeutics (ADTX), Algernon Pharmaceuticals (AGNPF), and Almirall (LBTSF).

Molecular Partners (OTCMKTS:MLLCF) and (DDXS) (OTCMKTS:DDXS) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, earnings, dividends, analyst recommendations and institutional ownership.

Analyst Ratings

This is a breakdown of current recommendations for Molecular Partners and (DDXS), as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Molecular Partners03202.40
(DDXS)0000N/A

Profitability

This table compares Molecular Partners and (DDXS)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Molecular PartnersN/AN/AN/A
(DDXS)N/AN/AN/A

Earnings & Valuation

This table compares Molecular Partners and (DDXS)'s revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Molecular PartnersN/AN/AN/AN/AN/A
(DDXS)N/AN/AN/AN/AN/A

Summary

Molecular Partners beats (DDXS) on 1 of the 1 factors compared between the two stocks.

Molecular Partners (OTCMKTS:MLLCF) and (TNGN) (OTCMKTS:TNGN) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, analyst recommendations, dividends, institutional ownership, valuation and risk.

Profitability

This table compares Molecular Partners and (TNGN)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Molecular PartnersN/AN/AN/A
(TNGN)N/AN/AN/A

Valuation & Earnings

This table compares Molecular Partners and (TNGN)'s top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Molecular PartnersN/AN/AN/AN/AN/A
(TNGN)N/AN/AN/AN/AN/A

Analyst Recommendations

This is a breakdown of current ratings for Molecular Partners and (TNGN), as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Molecular Partners03202.40
(TNGN)0000N/A

Summary

Molecular Partners beats (TNGN) on 1 of the 1 factors compared between the two stocks.

Molecular Partners (OTCMKTS:MLLCF) and Abattis Bioceuticals (OTCMKTS:ATTBF) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership and dividends.

Profitability

This table compares Molecular Partners and Abattis Bioceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Molecular PartnersN/AN/AN/A
Abattis BioceuticalsN/AN/AN/A

Valuation and Earnings

This table compares Molecular Partners and Abattis Bioceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Molecular PartnersN/AN/AN/AN/AN/A
Abattis BioceuticalsN/AN/AN/AN/AN/A

Analyst Ratings

This is a summary of current recommendations and price targets for Molecular Partners and Abattis Bioceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Molecular Partners03202.40
Abattis Bioceuticals0000N/A

Summary

Molecular Partners beats Abattis Bioceuticals on 1 of the 1 factors compared between the two stocks.

Molecular Partners (OTCMKTS:MLLCF) and ADiTx Therapeutics (NASDAQ:ADTX) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership and dividends.

Analyst Ratings

This is a summary of current recommendations and price targets for Molecular Partners and ADiTx Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Molecular Partners03202.40
ADiTx Therapeutics00103.00

Valuation and Earnings

This table compares Molecular Partners and ADiTx Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Molecular PartnersN/AN/AN/AN/AN/A
ADiTx TherapeuticsN/AN/AN/AN/AN/A

Profitability

This table compares Molecular Partners and ADiTx Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Molecular PartnersN/AN/AN/A
ADiTx TherapeuticsN/AN/AN/A

Algernon Pharmaceuticals (OTCMKTS:AGNPF) and Molecular Partners (OTCMKTS:MLLCF) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings and valuation.

Earnings and Valuation

This table compares Algernon Pharmaceuticals and Molecular Partners' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Algernon PharmaceuticalsN/AN/AN/AN/AN/A
Molecular PartnersN/AN/AN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Algernon Pharmaceuticals and Molecular Partners, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Algernon Pharmaceuticals0000N/A
Molecular Partners03202.40

Profitability

This table compares Algernon Pharmaceuticals and Molecular Partners' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Algernon PharmaceuticalsN/AN/AN/A
Molecular PartnersN/AN/AN/A

Summary

Molecular Partners beats Algernon Pharmaceuticals on 1 of the 1 factors compared between the two stocks.

Molecular Partners (OTCMKTS:MLLCF) and Almirall (OTCMKTS:LBTSF) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, risk, earnings and analyst recommendations.

Profitability

This table compares Molecular Partners and Almirall's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Molecular PartnersN/AN/AN/A
AlmirallN/AN/AN/A

Earnings and Valuation

This table compares Molecular Partners and Almirall's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Molecular PartnersN/AN/AN/AN/AN/A
AlmirallN/AN/AN/AN/AN/A

Analyst Recommendations

This is a summary of current ratings for Molecular Partners and Almirall, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Molecular Partners03202.40
Almirall01102.50


Molecular Partners Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
(DDXS) logo
DDXS
(DDXS)
0.5$0.00+0.0%$0.00N/A0.00
TNGN
(TNGN)
0.4N/AN/A$0.00N/A0.00Gap Down
Abattis Bioceuticals logo
ATTBF
Abattis Bioceuticals
0.4$0.01+0.0%$0.00N/A0.00Gap Up
ADiTx Therapeutics logo
ADTX
ADiTx Therapeutics
1.0$2.30+1.3%$0.00N/A0.00Earnings Announcement
Gap Up
Algernon Pharmaceuticals logo
AGNPF
Algernon Pharmaceuticals
0.0$0.13+0.0%$0.00N/A0.00News Coverage
Gap Down
Almirall logo
LBTSF
Almirall
0.5$15.15+1.5%$0.00N/A0.00
Apotheca Biosciences logo
CBDC
Apotheca Biosciences
0.4$0.06+0.0%$0.00N/A0.00
ARNI
Arno Therapeutics
0.5$0.01+0.0%$0.00N/A0.00
ASCLF
Ascletis Pharma
0.4$0.00+92,400.0%$0.00N/A0.00Gap Down
AXIM Biotechnologies logo
AXIM
AXIM Biotechnologies
0.4$0.67+10.4%$0.00N/A0.00
BXRXV
Baudax Bio
0.5N/AN/A$0.00N/A0.00High Trading Volume
BerGenBio ASA logo
BRRGF
BerGenBio ASA
0.7$3.52+0.0%$0.00N/A0.00
Cannabics Pharmaceuticals logo
CNBX
Cannabics Pharmaceuticals
0.4$0.19+0.0%$0.00N/A0.00Gap Up
ORHOF
CannaRoyalty
0.7$9.23+56.1%$0.00N/A0.00Gap Up
Cerebain Biotech logo
CBBT
Cerebain Biotech
0.0$0.05+0.0%$0.00N/A0.00
CGYG
China Longyi Group International
0.4$0.00+0.0%$0.00N/A0.00
Claritas Pharmaceuticals logo
KALTF
Claritas Pharmaceuticals
0.6$0.03+0.0%$0.00N/A0.00Gap Down
CLVLY
Clinuvel Pharmaceuticals
1.0$22.65+4.9%$0.00N/A0.00Gap Up
CELZ
Creative Medical Technology
0.5$0.03+0.0%$0.00N/A0.00News Coverage
Gap Down
Eastgate Biotech logo
ETBI
Eastgate Biotech
0.5$0.00+33.3%$0.00N/A0.00News Coverage
Gap Up
EMMBF
Emblem
0.6$1.40+1.4%$0.00N/A0.00
ENZC
Enzolytics
0.0$0.12+16.1%$0.00N/A0.00Gap Down
GB Sciences logo
GBLX
GB Sciences
0.5$0.05+0.0%$0.00N/A0.00News Coverage
Gap Down
Genfit logo
GNFTF
Genfit
0.5$4.17+0.0%$0.00N/A0.00News Coverage
GMXAY
GENMAB A/S/S
0.5$37.08+1.0%$0.00N/A0.00High Trading Volume
Genus logo
GENSF
Genus
0.7$66.00+0.0%$0.00N/A0.00
HALB
Halberd
0.0$0.03+0.0%$0.00N/A0.00News Coverage
Gap Down
HAVN Life Sciences logo
HAVLF
HAVN Life Sciences
0.0$0.63+0.4%$0.00N/A0.00News Coverage
Idorsia logo
IDRSF
Idorsia
0.5$25.00+4.2%$0.00N/A0.00
IPATF
ImmunoPrecise Antibodies
0.5N/AN/A$0.00N/A0.00High Trading Volume
IMLFF
InMed Pharmaceuticals
0.6N/AN/A$0.00N/A0.00High Trading Volume
Innovation Pharmaceuticals logo
IPIX
Innovation Pharmaceuticals
0.6$0.19+0.0%$0.00N/A0.00
Medican Enterprises logo
MDCN
Medican Enterprises
0.5$0.00+0.0%$0.00N/A0.00Gap Up
Mesoblast logo
MEOBF
Mesoblast
0.5$1.34+0.0%$0.00N/A0.00
MCURF
Mind Cure Health
0.0$0.27+0.9%$0.00N/A0.00News Coverage
Gap Down
Mind Medicine (MindMed) logo
MMEDF
Mind Medicine (MindMed)
1.1$3.23+7.4%$0.00N/A0.00Gap Down
MorphoSys logo
MPSYF
MorphoSys
0.0$93.05+0.0%$0.00N/A0.00
NRNVF
Nordic Nanovector ASA
0.0$1.64+0.0%$0.00N/A0.00High Trading Volume
Novozymes A/S logo
NVZMF
Novozymes A/S
0.4$74.15+5.7%$0.00N/A0.00Gap Up
BPSR
Organicell Regenerative Medicine
0.5$0.22+9.0%$0.00N/A0.00News Coverage
Gap Up
Oxurion logo
TBGNF
Oxurion
0.5$2.94+0.0%$0.00N/A0.00
Pharnext logo
PNEXF
Pharnext
0.0$3.99+0.0%$0.00N/A0.00
PTEO
Proteo
0.5$0.09+0.0%$0.00N/A0.00
PROT
Proteonomix
0.5$0.02+0.0%$0.00N/A0.00
ProtoKinetix logo
PKTX
ProtoKinetix
0.5$0.20+6.6%$0.00N/A0.00Gap Up
PureTech Health logo
PTCHF
PureTech Health
0.0$5.24+0.7%$0.00N/A0.00
RCPHF
Recipharm AB (publ)
1.0$16.05+0.0%$0.00N/A0.00High Trading Volume
Regen BioPharma logo
RGBP
Regen BioPharma
0.0N/AN/A$0.00N/A0.00News Coverage
Relief Therapeutics logo
RLFTF
Relief Therapeutics
0.5$0.22+4.5%$0.00N/A0.00News Coverage
Gap Down
BSSP
Reve Technologies
0.0$0.00+14.3%$0.00N/A0.00Gap Up
This page was last updated on 5/15/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.